Epidemiologic and Clinical Perspectives on Antipsychotic Treatment of Children and Adolescents

Olfson, Mark

doi:10.1177/070674371205701201

Cited by 6 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, the use of antipsychotics has risen in all developed countries (Verdoux et al 2010;Gyllenberg et al 2012;Olfson 2012). Possible reasons include a greater use of the atypical antipsychotics for the treatment of behavioral disorders ( Jensen et al 2007;Domino and Swartz 2008) and the treatment of high-risk patients in an effort to prevent psychosis though this practice has been strongly criticized (McGorry et al 2009).…”

Section: Introductionmentioning

confidence: 96%

Psychotropic Medication Use in French Children and Adolescents

Kovess

Choppin

Gao

et al. 2015

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 96%

Psychotropic Medication Use in French Children and Adolescents

Kovess

Choppin

Gao

et al. 2015

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…But only few antipsychotic drugs are licensed for those indications and for children and there is a lack of long-term efficacy and safety data [11]. Therefore, the treatment of youth with antipsychotics is subject to debate among clinicians, scientists and health policy makers [12]. …”

Section: Introductionmentioning

confidence: 99%

A multi-national comparison of antipsychotic drug use in children and adolescents, 2005–2012

Kalverdijk

Bachmann

Aagaard³

et al. 2017

Child Adolesc Psychiatry Ment Health

View full text Add to dashboard Cite

Over the last decades, an increase in antipsychotic (AP) prescribing and a shift from first-generation antipsychotics (FGA) to second-generation antipsychotics (SGA) among youth have been reported. However, most AP prescriptions for youth are off-label, and there are worrying long-term safety data in youth. The objective of this study was to assess multinational trends in AP use among children and adolescents. A repeated cross-sectional design was applied to cohorts from varied sources from Denmark, Germany, the Netherlands, the United Kingdom (UK) and the United States (US) for calendar years 2005/2006–2012. The annual prevalence of AP use was assessed, stratified by age group, sex and subclass (FGA/SGA). The prevalence of AP use increased from 0.78 to 1.03% in the Netherlands’ data, from 0.26 to 0.48% in the Danish cohort, from 0.23 to 0.32% in the German cohort, and from 0.1 to 0.14% in the UK cohort. In the US cohort, AP use decreased from 0.94 to 0.79%. In the US cohort, nearly all ATP dispensings were for SGA, while among the European cohorts the proportion of SGA dispensings grew to nearly 75% of all AP dispensings. With the exception of the Netherlands, AP use prevalence was highest in 15–19 year-olds. So, from 2005/6 to 2012, AP use prevalence increased in all youth cohorts from European countries and decreased in the US cohort. SGA were favoured in all countries’ cohorts.

show abstract

“…The increase in psychotropic prescribing to youth is consistent with national trends, reflecting the increased use of atypical antipsychotics and polypharmacy usually associated with disruptive behavior disorders (e.g., Alessi-Severini et al, 2012;Aparasu & Bhatara, 2007;Comer, Olfson, & Mojtabai, 2010;Lyons et al, 2004;Matone et al, 2012;Olfson et al, 2006;Olfson, 2012;Patten, Waheed, & Bresee, 2012). In writing about the same phenomenon in psychiatrically hospitalized children, Carlson (2013) reported that the increased use of atypical antipsychotics and polypharmacy reflects how seriously disturbed children with ADHD + ODD (Oppositional Defiant Disorder) are currently medicated.…”

Section: Polypharmacy Trendsmentioning

confidence: 68%